Cost-effectiveness of HPV vaccination in the Netherlands

Jul 01, 2009

Even under favorable assumptions, including lifelong protection against 70% of all cervical cancers and no side effects, vaccination against the human papillomavirus (HPV) is not cost-effective in the Netherlands, according to a study published online July 1 in the Journal of the National Cancer Institute.

Researchers conducted the study because the cost effectiveness of HPV vaccination may be limited by the low number of cervical cases and deaths in the region associated with the current Dutch screening program.

In the study, Inge M.C.M. de Kok of the Department of Public Health at Erasmus MC, University Medical Center in Rotterdam, the Netherlands, and colleagues estimated the costs and effects of adding HPV vaccination to the current program (screening only) using a microsimulation screening analysis model.

They found that adding HPV vaccination was not cost-effective, even under favorable assumptions.

"To become cost-effective, the price would have to be decreased considerably, depending on the effectiveness of the vaccine," the authors write.

Source: Journal of the National Cancer Institute (news : web)

Explore further: AstraZeneca cancer drug, companion test approved

add to favorites email to friend print save as pdf

Related Stories

Study on government's controversial choice of HPV vaccine

Jul 18, 2008

The UK government may save up to £18.6 million a year by deciding to use the HPV vaccine Cervarix, given that it is equally effective as the more expensive Gardasil in preventing cervical abnormalities, according to a study ...

Cervical cancer screening: Too many are left unprotected

Sep 19, 2007

The decline in cervical cancer is a success story of cancer research. Although there are reasons to be optimistic about even further decreases in cervical cancer incidence, there still remain some women who are not screened. ...

Recommended for you

Bone loss drugs may help prevent endometrial cancer

2 hours ago

A new analysis suggests that women who use bisphosphonates—medications commonly used to treat osteoporosis and other bone conditions—have about half the risk of developing endometrial cancer as women who do not use the ...

Putting the brakes on cancer

Dec 19, 2014

A study led by the University of Dundee, in collaboration with researchers at our University, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.